• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Sivextro (tedizolid phosphate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sivextro (tedizolid phosphate)

  • Profile

Profile

Contact Information

Contact: Merck Sharp & Dohme Corp.
Website: http://www.sivextro.com/dosing-administration/

Currently Enrolling Trials

    Show More

    General Information

    Sivextro (tedizolid phosphate) is an antibacterial agent of the oxazolidinone class.

    Sivextro is specifically indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus inosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.

    Mechanism of Action

    Sivextro (tedizolid phosphate) is an antibacterial agent of the oxazolidinone class. The antibacterial activity of tedizolid is mediated by binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis. Tedizolid inhibits bacterial protein synthesis through a mechanism of action different from that of other non-oxazolidinone class antibacterial drugs; therefore, cross-resistance between tedizolid and other classes of antibacterial drugs is unlikely. The results of in vitro time-kill studies show that tedizolid is bacteriostatic against enterococci, staphylococci and streptococci.

    Side Effects

    Adverse effects associated with the use of Sivextro may include, but are not limited to, the following:

    • nausea
    • headache
    • diarrhea
    • vomiting
    • dizziness

    Dosing/Administration

    Sivextro is supplied as a tablet or solution, for oral and/or intravenous administration. The recommended dosage of Sivextro is 200 mg administered once daily for six days either orally (with or without food) or as an intravenous (IV) infusion.

    Clinical Trial Results

    The FDA approval of Sivextro was based on two multicenter, multinational, randomized, double-blind, non-inferiority trials. Both trials compared Sivextro 200 mg once daily for six days versus linezolid 600 mg every 12 hours for 10 days. In trial 1, subjects were treated with oral therapy, while in trial 2, subjects could receive oral therapy after a minimum of one day of intravenous therapy. Subjects with cellulitis/erysipelas, major cutaneous abscess or wound infection were enrolled in the trials. Subjects with wound infections could have received aztreonam and/or metronidazole as adjunctive therapy for gram-negative bacterial coverage, if needed. The intent-to-treat (ITT) patient population included all randomized patients. 

    Trial 1
    This trial randomized 323 subjects to Sivextro and 326 subjects to linezolid. The overall median surface area of infection was 190 cm2. The types of ABSSSI included were cellulitis/erysipelas (40 percent), wound infection (30 percent) and major cutaneous abscess (30 percent). In addition to local signs and symptoms of infection, subjects were required to have at least one regional or systemic sign of infection at baseline. The primary endpoint was early clinical response defined as no increase from baseline lesion area at 48-72 hours after the first dose and oral temperature of ≤37.6°C, confirmed by a second temperature measurement within 24 hours in the ITT population. The percentage of responders to the primary endpoint was 79.3 percent and 79.1 percent in the Sivextro and linezolid arms, respectively. 

    Trial 2
    This trial randomized 332 subjects to Sivextro and 334 subjects to linezolid. The overall median surface area of infection was 231 cm2. The types of ABSSSI included were cellulitis/erysipelas (50 percent), wound infection (30 percent) and major cutaneous abscess (20 percent). In addition to local signs and symptoms of infection, subjects were also required to have at least one regional or systemic sign of infection at baseline. The primary endpoint was early clinical response defined as at least a 20 percent decrease from baseline lesion area at 48-72 hours after the first dose in the ITT population. The percentage of responders to the primary endpoint was 85.2 percent and 82.6 percent in the Sivextro and linezolid arms, respectively. 

     

     

    Approval Date: 2014-06-01
    Company Name: Cubist Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing